Study identifier:D0570C00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A single-centre, randomised, double-blind, double-dummy, placebo controlled, 4-way crossover Phase I study to investigate the effect of 2 single doses (400 μg and 1200 µg) of inhaled AZD3199 on QT/QTc interval, compared to placebo, using moxifloxacin (Avelox®) as a positive control, in healthy male volunteers
Chronic Obstructive Pulmonary Disease
Phase 1
Yes
AZD3199, Moxifloxacin
Male
40
Interventional
18 Years - 45 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 400 µg AZD3199 + moxifloxacin placebo | Drug: AZD3199 Single dose, oral inhalation |
Experimental: 2 1200 µg AZD3199 + moxifloxacin placebo | Drug: AZD3199 Single dose, oral inhalation |
Active Comparator: 3 AZD3199 placebo + moxifloxacin 400 mg | Drug: Moxifloxacin Single dose, oral encapsulated tablet Other Name: Avelox® |
Placebo Comparator: 4 AZD3199 placebo + moxifloxacin placebo | Other: Placebo comparator Single dose, oral inhalation |